Urogen Pharma Ltd (NASDAQ:URGN)
| 9.27 Delayed Data As of 3:59pm ET |  0.00 / 0.00%Today’s Change | 4.85 Today|||52-Week Range 12.63 | +4.51% Year-to-Date |
Latest URGN News | Press Releases
| BENDER ROBERT & ASSOCIATES Cuts Portfolio Down to Size in 4th Quarter Feb 02 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 9.27 |
| Today’s open | 9.35 |
| Day’s range | 9.26 - 9.60 |
| Volume | 1,941 |
| Average volume (3 months) | 81,950 |
| Market cap | $214.0M |
Data as of 3:59pm ET, 02/06/2023
Growth & Valuation
| Earnings growth (last year) | +15.93% |
| Earnings growth (this year) | +8.90% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | +307.17% |
| P/E ratio | NM |
| Price/Sales | 4.42 |
| Price/Book | 24.75 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| KMDAKamada Ltd | -0.18 | -3.84% |
| XXII22nd Century Group I... | -0.03 | -2.83% |
| LRMRLarimar Therapeutics... | +0.16 | +3.00% |
| XOMAXOMA Corp | -0.14 | -0.68% |
Data as of 3:59pm ET, 02/06/2023
Financials
| Next reporting date | March 16, 2023 |
| EPS forecast (this quarter) | -$1.07 |
| Annual revenue (last year) | $48.0M |
| Annual profit (last year) | -$110.8M |
| Net profit margin | -230.67% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Princeton, New Jersey |
Forecasts
